Overview

* Amneal Q2 2025 net revenue rises 3% but misses analyst expectations, per LSEG data

* Adjusted EBITDA for Q2 2025 increases 13% to $184 mln, reflecting higher revenue and gross margin

* Co raises full year 2025 guidance, citing strong product uptake and FDA approval

Outlook

* Amneal raises 2025 adjusted EBITDA guidance to $665 mln - $685 mln

* Company increases 2025 adjusted EPS forecast to $0.70 - $0.75

* Amneal boosts 2025 operating cash flow outlook to $275 mln - $305 mln

* Company expects 2025 net revenue between $3.0 bln and $3.1 bln

Result Drivers

* SPECIALTY SEGMENT - Specialty net revenue rose 23% due to strong performance of branded products like CREXONT and RYTARY

* DEBT REFINANCING - Successful debt refinancing reduced interest costs and extended maturities, improving financial position

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $724.51 $744.60

Revenue mln mln (4

Analysts

)

Q2 Net $35.61

Income mln

Q2 Gross $286.25

Profit mln

Q2 $111.37

Operatin mln

g Income

Q2 $51.71

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Amneal Pharmaceuticals Inc ( AMRX ) is $12.00, about 33.7% above its August 4 closing price of $7.96

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)